- Country: USA
- Summary: Anti-Anthrax Toxin Antibody, Raxibacumab
- UST Ref No: 88938832
- Deadline: 19 Sep 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: FDA-23-1268046
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Request for Quotation: FDA-23-1268046
Posted Date: September 14, 2023
Response Date: September 19, 2023, 12:00 p.m Eastern Time.
Interested parties may identify in writing their interest and capability to respond by no later than September 19, 12:00 p.m. Eastern Time. Please email responses to Elena Tatarov at Elena.Tatarov@fda.hhs.gov.
Indicate company-s SAM.gov Unique Entity ID on the quote. The subject line shall read: FDA-23-1268046 - ANTI-ANTHRAX TOXIN ANTIBODY, RAXIBACUMAB
This is a combined synopsis/solicitation for commercial supplies prepared in accordance with the format in FAR 12.6 as supplemented with FAR 8 and additional information included in this notice. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2023-05. This solicitation is issued as a Request for Quote (RFQ).
This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued.
The Government intends to issue a Firm Fixed Price Task Order.
NAICS Code: 325414
Line Item Structure: The following is a contract line item number(s), quantities, and units of measure, (including option(s), if applicable):
Line Item 0001 - FDA-23-1268046 - ANTI-ANTHRAX TOXIN ANTIBODY, RAXIBACUMAB
Background
Anthrax is a life-threatening disease caused by infection with Bacillus anthracis. The deliberate human use of anthrax has emerged as a biological terrorism threat, highlighted by a series of deadly attacks through the postal service in the form of a finely powdered preparation of anthrax spores in 2001. Anti-anthrax toxin antibodies have been developed as therapeutic for prophylaxis and treatment of inhaled anthrax. Potency control is essential for quality assurance of the anti-anthrax toxin therapeutic antibodies. Our laboratory has been developing a new cell-based potency assay for anti-anthrax toxin therapeutics that reflects the in ... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINAnti-Anthrax Toxin Antibody, Raxibacumab - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Anti-Anthrax Toxin Antibody, Raxibacumab. This tender is published on USARFP under UST Ref No: 88938832 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-09-19.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
